Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-01-24

FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)

View source ↗

Summary

FDA approved Amneal Pharmaceuticals' supplemental application for aripiprazole (ARIPIPRAZOLE) under the ANDA pathway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARIPIPRAZOLE (Aripiprazole)

Snippet

SUPPL AP for ARIPIPRAZOLE (ARIPIPRAZOLE)